Therefore, further studies are necessary to discern how chronic LC activation modulates the pro- or anti-inflammatory profile in EAE along to the identification of the immune populations participating in the therapeutic effect (Th1, Th2, Th17, CD11b, CD45, CD68, CD80, CD163, CD206, MCP1 lymphocytes) that might become key pieces of MS and its clinical management. This evidence concerns the gene CD80 and myeloid sarcoma.